We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+37.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.62B
AUM Growth
+$630M
(+32%)
Cap. Flow
+$142M
Cap. Flow
% of AUM
5.42%
Top 10 Holdings %
Top 10 Hldgs %
54.13%
Holding
172
New
46
Increased
29
Reduced
19
Closed
33
Avg Time Held Equity + Options
4.2
quarters
Top 10 Avg Time Held Equity + Options
5.4
quarters
Top 20 Avg Time Held Equity + Options
5.4
quarters
Avg Time Held Equity only
4.4
quarters
Top 10 Avg Time Held Equity only
5.4
quarters
Top 20 Avg Time Held Equity only
5.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$64.1M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$36.1M |
| 3 |
XLRN
Acceleron Pharma
XLRN
|
+$31.4M |
| 4 |
Puma Biotechnology
PBYI
|
+$17.7M |
| 5 |
Cymabay Therapeutics
CBAY
|
+$15.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$42.4M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$36.7M |
| 3 |
Radius Health, Inc.
RDUS
|
+$29.2M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$20.9M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.22% |
| 2 | Miscellaneous | 1.22% |
| 3 | Industrials | 0.33% |
| 4 | Consumer Staples | 0.16% |
| 5 | Consumer Discretionary | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Neurocrine Biosciences
NBIX
$14.4B
| $294M | 11.22% |
4,791,589
+1,214,000
| +34% | +$64.1M |
2013 Q2
17 quarters
|
|
2
DELISTED
Amicus Therapeutics
FOLD
| $270M | 10.31% |
17,888,597
+591,925
| +3% | +$7.83M |
2014 Q1
14 quarters
|
|
3
Alnylam Pharmaceuticals
ALNY
$30.4B
| $210M | 8.03% |
1,788,802
-43,959
| -2% | -$3.75M |
2016 Q4
3 quarters
|
|
|
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $132M | 5.06% |
4,264,066
+330,139
| +8% | +$9.28M |
2015 Q3
8 quarters
|
|
|
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
| $129M | 4.91% |
3,670,357
+222,055
| +6% | +$3.01M |
2016 Q3
4 quarters
|
|
|
6
Puma Biotechnology
PBYI
$531M
| $111M | 4.23% |
923,820
+190,500
| +26% | +$17.7M |
2017 Q2
1 quarter
|
|
|
LJPC
7
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $75M | 2.87% |
2,157,011
| – | – |
2014 Q3
12 quarters
|
|
8
Travere Therapeutics
TVTX
$4.9B
| $66.9M | 2.55% |
2,686,204
+13,895
| +0.5% | +$306K |
2014 Q1
14 quarters
|
|
|
AVXS
9
DELISTED
AveXis, Inc. Common Stock
AVXS
| $64.9M | 2.48% |
671,181
+400,000
| +148% | +$36.1M |
2016 Q1
6 quarters
|
|
|
CORI
10
DELISTED
Corium International, Inc.
CORI
| $64.8M | 2.48% |
5,847,133
| – | – |
2017 Q1
2 quarters
|
|
|
XLRN
11
DELISTED
Acceleron Pharma
XLRN
| $60.3M | 2.3% |
1,616,259
+905,000
| +127% | +$31.4M |
2014 Q2
13 quarters
|
|
|
TSRO
12
DELISTED
TESARO, Inc.
TSRO
| $50.2M | 1.92% |
388,651
+29,100
| +8% | +$3.61M |
2013 Q2
17 quarters
|
|
13
Regenxbio
RGNX
$513M
| $47.5M | 1.81% |
1,441,186
+70,000
| +5% | +$1.58M |
2015 Q3
8 quarters
|
|
|
DOVA
14
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $42.6M | 1.63% |
1,754,015
+47,516
| +3% | +$1.13M |
2017 Q2
1 quarter
|
|
15
Iovance Biotherapeutics
IOVA
$6.6B
| $36.6M | 1.4% |
4,726,114
+363,000
| +8% | +$2.3M |
2015 Q1
10 quarters
|
|
|
NXTM
16
DELISTED
NxStage Medical Inc.
NXTM
| $34.9M | 1.33% |
1,264,523
-291,000
| -19% | -$7.76M |
2016 Q2
5 quarters
|
|
17
AnaptysBio
ANAB
$1.38B
| $34.3M | 1.31% |
982,269
+30,000
| +3% | +$809K |
2017 Q1
2 quarters
|
|
18
Akebia Therapeutics
AKBA
$219M
| $32.1M | 1.22% |
1,630,000
+530,000
| +48% | +$8.15M |
2015 Q3
8 quarters
|
|
19
Xencor
XNCR
$1.86B
| $29.6M | 1.13% |
1,293,095
| – | – |
2013 Q4
15 quarters
|
|
20
DELISTED
Blueprint Medicines
BPMC
| $29.6M | 1.13% |
424,661
-20,000
| -4% | -$1.07M |
2015 Q2
9 quarters
|
|
21
Intuitive Surgical
ISRG
$151B
| $26.4M | 1.01% |
226,755
+40,500
| +22% | +$4.41M |
2017 Q2
1 quarter
|
|
22
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $25.3M | 0.97% |
218,861
| – | – |
2015 Q1
10 quarters
|
|
23
CytomX Therapeutics
CTMX
$527M
| $25.3M | 0.97% |
1,390,381
| – | – |
2016 Q4
3 quarters
|
|
24
DBV Technologies S.A. American Depositary Shares
DBVT
$600M
| $24.5M | 0.93% |
57,642
-1,535
| -3% | -$658K |
2015 Q2
9 quarters
|
|
25
Humana
HUM
$52.1B
| $24.4M | 0.93% |
100,000
+21,907
| +28% | +$5.37M |
2016 Q4
3 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q3 2017 Portfolio in Review
As of Q3 2017, Perceptive Advisors held 172 positions worth $2.62B, up 32% from $1.99B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Perceptive Advisors deployed $142M of net new capital in Q3 2017, opening 46 new positions and adding to 29 existing holdings. Its largest new stake was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $42.4M trimmed.
- Perceptive Advisors's largest Q3 2017 buy was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
- Perceptive Advisors added most to Neurocrine Biosciences in Q3 2017, an estimated $64.1M increase.
- Perceptive Advisors's biggest Q3 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $42.4M.
- Perceptive Advisors fully exited Sarepta Therapeutics in Q3 2017, selling an estimated $36.7M.
- Perceptive Advisors's ten largest holdings make up 54% of its $2.62B portfolio in Q3 2017.
- Perceptive Advisors opened 46 new positions and closed 33 in Q3 2017.
- Perceptive Advisors's portfolio value rose 32% quarter-over-quarter to $2.62B.
Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.